Valuation: CorMedix Inc.

Market Cap 661M 577M 533M 491M 925M 63.61B 946M 6.37B 2.5B 31.16B 2.48B 2.43B 107B P/E 2026 *
16.7x
P/E 2027 * 95.7x
Enterprise Value 661M 577M 533M 491M 925M 63.61B 946M 6.37B 2.5B 31.16B 2.48B 2.43B 107B EV / Sales 2026 *
1.97x
EV / Sales 2027 * 2.32x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day+1.57%
1 week+0.24%
Current month+7.26%
1 month-2.88%
3 months+13.94%
6 months+24.19%
Current year-27.60%
1 week 8.11
Extreme 8.11
8.53
1 month 7.5
Extreme 7.495
9.06
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap.
04/02/26 Free

Chief Executive Officer

77,156 0.0979%
04/02/26 Free

Chief Operating Officer

36,006 0.0457%
04/02/26 Free

General Counsel

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+0.24%-23.94%+117.57% 661M
-0.10%+3.21%+56.40%+20.77% 315B
-1.20%-2.43%+22.19%-8.40% 67.81B
+0.35%+2.11%+34.61%+93.22% 9.23B
+0.34%+0.51%+4.67%+0.09% 8.56B
+1.53%-3.64%-22.99%+3.93% 4.18B
-11.03%-12.07%-5.25%+15.98% 3.59B
+1.87%+3.36%-47.86%+27.51% 3.55B
-0.35%-0.87%+43.02%+63.23% 2.79B
-7.41%-2.37%+3.82%-22.47% 2.09B
Average -1.44%-1.52%+6.47%+31.14% 41.74B
Weighted average by Cap. -0.36%+1.02%+46.61%+17.28%

Financials

2026 *2027 *
Net sales 335M 292M 270M 249M 469M 32.22B 479M 3.22B 1.27B 15.78B 1.26B 1.23B 54.32B 285M 249M 230M 212M 400M 27.47B 408M 2.75B 1.08B 13.45B 1.07B 1.05B 46.31B
Net income 47.14M 41.2M 38.02M 35.04M 66.05M 4.54B 67.51M 454M 179M 2.22B 177M 173M 7.65B 8.61M 7.52M 6.94M 6.4M 12.06M 829M 12.33M 82.99M 32.64M 406M 32.33M 31.63M 1.4B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
17/07/26 $8.420 +1.57% 694,737
16/07/26 $8.290 -1.54% 874,704
15/07/26 $8.420 +1.81% 648,439
14/07/26 $8.270 -0.60% 806,842
13/07/26 $8.320 -0.95% 886,189
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.420USD
Average target price
15.00USD
Spread / Average Target
+78.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock